Skip to content

DBT and Escitalopram in Borderline Personality Disorder

Effects of Dialectical Behavioral Therapy and Escitalopram on Impulsive Aggression, Affective Instability and Cognitive Processing in Borderline Personality Disorder

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00255554
Enrollment
Unknown
Registered
2005-11-21
Start date
Unknown
Completion date
Unknown
Last updated
2005-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Borderline Personality Disorder

Keywords

Borderline Personality Disorder, BPD, Dialectical Behavior Therapy, DBT, Escitalopram, Lexapro

Brief summary

Subjects will receive six months of DBT, consisting of one 90-minute group and one 60-minute individual session per week as well as telephone availability of the individual therapist. Half the subjects will concurrently receive escitalopram while half will receive placebo, in a randomized double-blind design.

Interventions

DRUGEscitalopram

Sponsors

Bronx VA Medical Center
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

Is a male or female between 18 and 60 who meets criteria for Borderline Personality Disorder and has been off psychotropic medications for at least 2 weeks (6 weeks for fluoxetine). \-

Exclusion criteria

Meets criteria for Schizophrenia, Bipolar Disorder, Mental Retardation, current or recent Substance Dependence or a current Major Depressive Episode. Subjects also should not currently be in individual psychotherapy. (Case management and work therapy programs are allowed.) \-

Design outcomes

Primary

MeasureTime frame
Measures of impulsivity, aggression, affective impulsivity, immediate and delayed memory, and cognitive processing at baseline, 6 months and 9 months

Countries

United States

Contacts

Primary ContactEmily Hart
mpgroup@mssm.edu212-241-0441

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026